NZ585777A - Compositions and methods of enhancing immune responses to eimeria - Google Patents

Compositions and methods of enhancing immune responses to eimeria

Info

Publication number
NZ585777A
NZ585777A NZ585777A NZ58577708A NZ585777A NZ 585777 A NZ585777 A NZ 585777A NZ 585777 A NZ585777 A NZ 585777A NZ 58577708 A NZ58577708 A NZ 58577708A NZ 585777 A NZ585777 A NZ 585777A
Authority
NZ
New Zealand
Prior art keywords
eimeria
compositions
methods
immune responses
enhancing immune
Prior art date
Application number
NZ585777A
Other languages
English (en)
Inventor
Walter Bottje
Billy Hargis
Luc Berghman
Young Min Kwon
Kimberly Cole
Mandy Cox
Sherryll Layton
Said El-Ashram
John Barta
Guillermo Tellez
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Univ Guelph
Said El Ashram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys, Univ Guelph, Said El Ashram filed Critical Univ Arkansas
Publication of NZ585777A publication Critical patent/NZ585777A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ585777A 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria NZ585777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98461207P 2007-11-01 2007-11-01
PCT/US2008/082254 WO2009059298A2 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancinc immune responses to eimeria

Publications (1)

Publication Number Publication Date
NZ585777A true NZ585777A (en) 2012-09-28

Family

ID=40591796

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ585777A NZ585777A (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria
NZ601880A NZ601880A (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601880A NZ601880A (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria

Country Status (14)

Country Link
US (3) US8956849B2 (https=)
EP (2) EP3097926B1 (https=)
JP (1) JP5480812B2 (https=)
CN (2) CN103893747B (https=)
AU (1) AU2008318357B2 (https=)
BR (1) BRPI0819229B1 (https=)
CA (3) CA2704422C (https=)
DK (2) DK3097926T3 (https=)
ES (2) ES2761693T3 (https=)
HU (2) HUE047164T2 (https=)
NZ (2) NZ585777A (https=)
PL (2) PL3097926T3 (https=)
PT (2) PT3097926T (https=)
WO (1) WO2009059298A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) * 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
WO2013123412A1 (en) * 2012-02-17 2013-08-22 Children's Medical Center Corporation Conformation-stabilized trap antigens
AR094791A1 (es) * 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2016259703B2 (en) 2015-05-08 2021-12-23 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110468069B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种干酪乳杆菌yfi-5及其在抗鲤疱疹病毒ii型中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
CA2143299A1 (en) 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5565321A (en) * 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
ATE309267T1 (de) * 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
ES2179187T3 (es) 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
IL136731A0 (en) 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
DE69939264D1 (de) 1998-09-04 2008-09-18 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen-träger
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
WO2001026608A2 (en) * 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
TR200401569T4 (tr) 1999-12-28 2004-07-21 Akzo Nobel N.V. Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
DE60112413T2 (de) 2000-03-17 2006-06-01 Pharmacia & Upjohn Co. Llc, Kalamazoo Ssa inaktivierte salmonella impfstoffe
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7811816B2 (en) 2001-05-15 2010-10-12 Ortho-Mcneil Pharmaeutical, Inc. Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell
ZA200400479B (en) * 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
CN100348608C (zh) * 2001-07-06 2007-11-14 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
ES2309224T3 (es) * 2001-12-21 2008-12-16 Immunex Corporation Polipeptidos recombinantes.
ATE421249T1 (de) * 2002-02-13 2009-02-15 Immunology Lab Inc Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
CA2526895A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
AU2006301171B9 (en) 2005-10-07 2012-03-29 Proyecto De Biomedicina Cima, S.L. Immunostimulatory combination for the prophylactics and treatment of hepatitis C
EP1951862B1 (en) 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
DE102005054643B3 (de) 2005-11-10 2007-02-15 Assa Abloy Sicherheitstechnik Gmbh Schließzylinder
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
FR2898905B1 (fr) * 2006-03-24 2008-05-09 Rhodia Recherches & Tech Composition polyisocyanate a proprietes anti-chocs ameliorees
WO2008027394A2 (en) * 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) * 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
ES2560871T3 (es) * 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) * 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
ES2538122T3 (es) * 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
US8316310B2 (en) 2008-08-05 2012-11-20 International Business Machines Corporation System and method for human identification proof for use in virtual environments
PL2184229T3 (pl) * 2008-11-11 2013-04-30 Agustawestland Spa Wirnik śmigłowca
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
ES2643646T3 (es) * 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP3753567A1 (en) * 2011-10-11 2020-12-23 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
WO2014043215A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System Bi-specifc diabodies for masking and targeting vaccines
US20150297714A1 (en) * 2012-10-29 2015-10-22 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
AR094791A1 (es) * 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) * 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US20170196971A1 (en) * 2014-06-05 2017-07-13 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
TWI761348B (zh) * 2016-05-27 2022-04-21 美商艾伯維生物醫療股份有限公司 抗cd40抗體及其用途
IL308824A (en) * 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof

Also Published As

Publication number Publication date
JP2011503003A (ja) 2011-01-27
PT3097926T (pt) 2020-01-08
US8956849B2 (en) 2015-02-17
CA3156538A1 (en) 2009-05-07
US10842858B2 (en) 2020-11-24
CN103893747B (zh) 2016-01-06
CA3156538C (en) 2023-12-12
ES2599905T3 (es) 2017-02-06
DK2214701T3 (en) 2016-12-12
US10016493B2 (en) 2018-07-10
EP2214701B1 (en) 2016-08-03
HUE047164T2 (hu) 2020-04-28
HUE030655T2 (en) 2017-05-29
CA2704422C (en) 2019-09-24
BRPI0819229A2 (pt) 2015-05-05
WO2009059298A2 (en) 2009-05-07
NZ601880A (en) 2013-12-20
WO2009059298A8 (en) 2010-08-05
AU2008318357A2 (en) 2010-06-24
JP5480812B2 (ja) 2014-04-23
US20150216954A1 (en) 2015-08-06
HK1146575A1 (zh) 2011-06-24
AU2008318357B2 (en) 2015-01-22
EP2214701A2 (en) 2010-08-11
CN101969990A (zh) 2011-02-09
WO2009059298A3 (en) 2009-09-24
PT2214701T (pt) 2016-11-02
EP3097926B1 (en) 2019-10-02
CN101969990B (zh) 2014-07-09
BRPI0819229B1 (pt) 2019-01-22
US20110111015A1 (en) 2011-05-12
PL2214701T3 (pl) 2017-01-31
CA3051748A1 (en) 2009-05-07
EP3097926A1 (en) 2016-11-30
ES2761693T3 (es) 2020-05-20
DK3097926T3 (da) 2019-12-16
CN103893747A (zh) 2014-07-02
CA3051748C (en) 2022-07-12
PL3097926T3 (pl) 2020-04-30
CA2704422A1 (en) 2009-05-07
US20180333474A1 (en) 2018-11-22
AU2008318357A1 (en) 2009-05-07
EP2214701A4 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
UA110806C2 (uk) Мікобактеріальна антигенна композиція
NZ702839A (en) Vaccine and methods to reduce campylobacter infection
PH12012500849A1 (en) Mycobacterial vaccines
NZ601345A (en) Combination adjuvant formulation
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
NZ757882A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
MY157239A (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
EA201391548A1 (ru) Иммуногенная композиция
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EP3932418A3 (en) Peptides for use in promoting transport of glucose
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2015107363A3 (en) Mycobacterial antigen composition
NZ596501A (en) Casb7439 constructs
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2013012875A3 (en) Bacterial rnas as vaccine adjuvants
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX2017016438A (es) Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit.
MX2013001383A (es) Vacuna anti-coccidial.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: UNIVERSITY OF GUELPH, CA

Free format text: OLD OWNER(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; THE TEXAS AANDM UNIVERSITY SYSTEM; UNIVERSITY OF GUELPH; WALTER BOTTJE; BILLY HARGIS; LUC BERGHMAN; YOUND MIN KWON; KIMBERLY COLE; MANDY COX; SHERRYLL; SAID ELASHRAM; JOHN BARTA; GUILLERMO TELLEZ

Owner name: THE TEXAS AANDM UNIVERSITY SYSTEM, US

Free format text: OLD OWNER(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; THE TEXAS AANDM UNIVERSITY SYSTEM; UNIVERSITY OF GUELPH; WALTER BOTTJE; BILLY HARGIS; LUC BERGHMAN; YOUND MIN KWON; KIMBERLY COLE; MANDY COX; SHERRYLL; SAID ELASHRAM; JOHN BARTA; GUILLERMO TELLEZ

Owner name: SAID EL-ASHRAM, CA

Free format text: OLD OWNER(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; THE TEXAS AANDM UNIVERSITY SYSTEM; UNIVERSITY OF GUELPH; WALTER BOTTJE; BILLY HARGIS; LUC BERGHMAN; YOUND MIN KWON; KIMBERLY COLE; MANDY COX; SHERRYLL; SAID ELASHRAM; JOHN BARTA; GUILLERMO TELLEZ

Owner name: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARK, US

Free format text: OLD OWNER(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; THE TEXAS AANDM UNIVERSITY SYSTEM; UNIVERSITY OF GUELPH; WALTER BOTTJE; BILLY HARGIS; LUC BERGHMAN; YOUND MIN KWON; KIMBERLY COLE; MANDY COX; SHERRYLL; SAID ELASHRAM; JOHN BARTA; GUILLERMO TELLEZ

S245 Proceeding according section 24(5): dispute between joint applicants, whether or in what manner the application should be proceeded with
S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 NOV 2015 BY AJ PARK

Effective date: 20130419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2016 BY THOMSON REUTERS

Effective date: 20151030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2017 BY THOMSON REUTERS

Effective date: 20161022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2018 BY THOMSON REUTERS

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2019 BY THOMSON REUTERS

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2021 BY COMPUTER PACKAGES INC

Effective date: 20201020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2022 BY COMPUTER PACKAGES INC

Effective date: 20211030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2023 BY COMPUTER PACKAGES INC

Effective date: 20221030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2024 BY COMPUTER PACKAGES INC

Effective date: 20231030

LAPS Patent lapsed